source
- Kardigan targets $320 million IPO to fund three late-stage heart drugsKardigan, a biotech focused on cardiovascular therapies, announced plans for an initial public offering that aims to raise about $320 million. The proceeds are intended to support the development…
- Enliven Therapeutics' early-stage study shows 48% major molecular response in CML patientsA targeted therapy from Enliven Therapeutics, ELVN-001, produced major molecular responses in 48% of participants with chronic myeloid leukemia (CML) in a 24‑week, early‑stage trial. The study eval…